Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021.

Authors :: Seppälä E
Veneti L
Starrfelt J
Danielsen AS
Bragstad K
Hungnes O
Taxt AM
Watle SV
Meijerink H
Source :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2021 Sep; Vol. 26 (35).
Publication Year :: 2021
Abstract: Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0-27.4) and 64.6% (95% CI: 60.6-68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4-58.3) and 84.4% (95%CI: 81.8-86.5) against the Alpha variant.

Subjects :: COVID-19 Vaccines
Cohort Studies
Humans
Norway epidemiology
SARS-CoV-2
COVID-19
Vaccines

Language :: English
ISSN :: 1560-7917
Volume :: 26
Issue :: 35
Database :: MEDLINE
Journal :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Type :: Academic Journal
Accession number :: 34477054
Full Text :: https://doi.org/10.2807/1560-7917.ES.2021.26.35.2100793

Full Text Access

Tools